4 results on '"Feras Alissa"'
Search Results
2. Update on Progressive Familial Intrahepatic Cholestasis
- Author
-
Benjamin L. Shneider, Feras Alissa, and Ronald Jaffe
- Subjects
Pathology ,medicine.medical_specialty ,ATP Binding Cassette Transporter, Subfamily B ,Cirrhosis ,Cholestasis, Intrahepatic ,digestive system ,Gastroenterology ,Genes, Reporter ,Internal medicine ,medicine ,Humans ,ABCB11 ,ATP Binding Cassette Transporter, Subfamily B, Member 11 ,Adenosine Triphosphatases ,business.industry ,Progressive familial intrahepatic cholestasis ,Nutritional status ,Hepatology ,ABCB4 ,Prognosis ,medicine.disease ,Pedigree ,Familial intrahepatic cholestasis ,Mutation ,Pediatrics, Perinatology and Child Health ,ATP-Binding Cassette Transporters ,business ,Biliary tract disease - Abstract
Three distinct forms of familial intrahepatic cholestasis are the result of mutations in the ATP8B1, ABCB11, and ABCB4 genes. The pathophysiologies of the latter 2 of these diseases are well characterized and are the result of abnormalities in canalicular excretion of bile acids and phospholipids, respectively. The molecular pathophysiology of the systemic disease associated with mutations in ATP8B1 remains unclear. In all of these diseases, wide variations in clinical phenotypes have been observed. The variability can be ascribed at least in part to predicted genotype:phenotype correlations. Disease- and genotype-specific prognoses and therapeutic approaches may exist, although much more information needs to be ascertained before clinicians can confidently make decisions based on genetic information.
- Published
- 2008
- Full Text
- View/download PDF
3. Total Serum Bilirubin within 3 Months of Hepatoportoenterostomy Predicts Short-Term Outcomes in Biliary Atresia
- Author
-
Benjamin L. Shneider, John C. Magee, Saul J. Karpen, Elizabeth B. Rand, Michael R. Narkewicz, Lee M. Bass, Kathleen Schwarz, Peter F. Whitington, Jorge A. Bezerra, Nanda Kerkar, Barbara Haber, Philip Rosenthal, Yumirle P. Turmelle, Jean P. Molleston, Karen F. Murray, Vicky L. Ng, Kasper S. Wang, Rene Romero, Robert H. Squires, Ronen Arnon, Averell H. Sherker, Jeffrey Moore, Wen Ye, Ronald J. Sokol, Estella Alonso, Elizabeth Kaurs, Sue Kelly, Kevin Bove, James Heubi, Alexander Miethke, Greg Tiao, Julie Denlinger, Andrea Ferris, Amy Feldman, Cara Mack, Frederick Suchy, Shikha Sundaram, Johan Van Hove, Michelle Hite, Susanna Kantor, Todd Miller, Julia Smith, Becky VanWinkle, Kathleen Loomes, Henry Lin, David Piccoli, Pierre Russo, Nancy Spinner, Lindsay Brown, Emily Elgert, Jessi Erlichman, Feras Alissa, Douglas Lindblad, George Mazariegos, Roberto Ortiz-Aguayo, David Perlmutter, Rakesh Sindhi, Veena Venkat, Jerry Vockley, Kathy Bukauskas, Adam Kufen, Madeline Schulte, Laura Bull, Shannon Fleck, Camille Langlois, Jeffery Teckman, Vikki Kociela, Stacy Postma, Kathleen Harris, Molly Bozic, Girish Subbarao, Beth Byam, Ann Klipsch, Cindy Sawyers, Simon Horslen, Evelyn Hsu, Kara Cooper, Melissa Young, Binita Kamath, Maria DeAngelis, Constance O'Connor, Krista VanRoestel, Arpita Parmar, Claudia Quammie, Kelsey Hung, Stephen Guthery, Kyle Jensen, Ann Rutherford, Nanda Kerker, Sonia Michail, Danny Thomas, Catherine Goodhue, Nikita Gupta, Mariam Vos, Liezl de la Cruz-Tracey, Dana Hankerson-Dyson, Rita Tory, Taieshia Turner-Green, Allison Wellons, Mary Brandt, Milton Finegold, Sanjiv Harpavat, Paula Hertel, Daniel Leung, Loriel Liwanag, Richard Thompson, Sherry Brown, Edward Doo, Jay Hoofnagle, Sherry Hall, Rebecca Torrance, Jameisha Brown, Kimberly Kafka, Robert Merion, and Cathie Spino
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Area under the curve ,Liver transplantation ,medicine.disease ,Hepatoportoenterostomy ,Gastroenterology ,Surgery ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Multicenter study ,Biliary atresia ,030225 pediatrics ,Internal medicine ,Pediatrics, Perinatology and Child Health ,medicine ,Biomarker (medicine) ,030211 gastroenterology & hepatology ,business ,Prospective cohort study - Abstract
Objectives To prospectively assess the value of serum total bilirubin (TB) within 3 months of hepatoportoenterostomy (HPE) in infants with biliary atresia as a biomarker predictive of clinical sequelae of liver disease in the first 2 years of life. Study design Infants with biliary atresia undergoing HPE between June 2004 and January 2011 were enrolled in a prospective, multicenter study. Complications were monitored until 2 years of age or the earliest of liver transplantation (LT), death, or study withdrawal. TB below 2 mg/dL (34.2 μM) at any time in the first 3 months (TB Results Fifty percent (68/137) of infants had TB P P P P P = .0002), LT (OR 12.4, 95% CI 5.3-28.7, P P Conclusions Infants whose TB does not fall below 2.0 mg/dL within 3 months of HPE were at high risk for early disease progression, suggesting they should be considered for LT in a timely fashion. Interventions increasing the likelihood of achieving TB Trial registration ClinicalTrials.gov: NCT00061828 and NCT00294684.
- Published
- 2016
- Full Text
- View/download PDF
4. Fulminant hepatic failure: Wilson's disease or autoimmune hepatitis? Implications for transplantation
- Author
-
Lisa A. Teot, J. Reyes, R. G. Santos, Feras Alissa, and Nadia A. Ameen
- Subjects
medicine.medical_specialty ,Adolescent ,Fulminant ,medicine.medical_treatment ,Autoimmune hepatitis ,Liver transplantation ,Asymptomatic ,Gastroenterology ,Fulminant hepatic failure ,Hepatolenticular Degeneration ,Internal medicine ,medicine ,Humans ,Hepatitis ,Transplantation ,business.industry ,Liver Failure, Acute ,medicine.disease ,digestive system diseases ,Surgery ,Liver Transplantation ,Wilson's disease ,Hepatitis, Autoimmune ,Liver ,Pediatrics, Perinatology and Child Health ,Female ,medicine.symptom ,business - Abstract
Fulminant hepatic failure (FHF) accounts for 10-15% of pediatric liver transplants in the USA annually. Because the onset of FHF may be the first presentation of Wilson's disease (WD) and autoimmune hepatitis (AIH) in previously asymptomatic adolescents, determination of the etiology of FHF is critical as treatment and prognosis differ between these two entities. Patients with AIH may be salvaged by medical treatment. On the contrary, liver transplantation is currently the only life saving therapeutic option available for patients with WD who present with fulminant liver failure. To establish the diagnosis of WD and AIH in the setting of FHF remains challenging for diagnosticians and decisions regarding liver transplantation may be necessary before a diagnosis is firmly established. We report a previously asymptomatic patient who presented with FHF and clinical and laboratory features suggestive of both WD and AIH and who underwent successful therapeutic liver transplantation before the diagnosis of WD could be confirmed.
- Published
- 2005
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.